Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AbbVie, Calico aim to advance cancer, neuro drugs through ten-year R&D pact; later extend deal

Executive Summary

In a collaboration that could run as long as ten years, AbbVie Inc., and biotech start-up Calico Life Sciences LLC (diseases related to aging) aim to create a leading San Francisco R&D facility focused on age-related diseases--particularly neurodegeneration and cancer--to discover and accelerate development of new therapies.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies